Oppenheimer Lowers Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $180.00

Ascendis Pharma A/S (NASDAQ:ASND) had its price target cut by analysts at Oppenheimer from $190.00 to $180.00 in a research note issued on Friday,Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s target price suggests a potential upside of 42.28% from the stock’s current price.

ASND has been the subject of a number of other reports. Evercore ISI increased their target price on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research report on Tuesday, September 17th. Stifel Nicolaus increased their price objective on Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a report on Friday. Bank of America boosted their target price on Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. TD Cowen upped their price target on Ascendis Pharma A/S from $157.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Finally, The Goldman Sachs Group boosted their price objective on Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $191.77.

Ascendis Pharma A/S Stock Up 1.8 %

ASND stock opened at $126.51 on Friday. The firm has a market cap of $7.67 billion, a PE ratio of -13.59 and a beta of 0.66. The business has a 50 day moving average of $132.30 and a 200-day moving average of $132.66. Ascendis Pharma A/S has a 12-month low of $90.13 and a 12-month high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The firm had revenue of $38.75 million during the quarter, compared to analysts’ expectations of $94.74 million. On average, research analysts expect that Ascendis Pharma A/S will post -7.35 earnings per share for the current year.

Institutional Trading of Ascendis Pharma A/S

A number of large investors have recently modified their holdings of ASND. SG Americas Securities LLC purchased a new position in Ascendis Pharma A/S in the first quarter worth $288,000. ProShare Advisors LLC boosted its holdings in shares of Ascendis Pharma A/S by 9.9% in the 1st quarter. ProShare Advisors LLC now owns 4,025 shares of the biotechnology company’s stock worth $608,000 after purchasing an additional 361 shares in the last quarter. Acadian Asset Management LLC lifted its position in Ascendis Pharma A/S by 1,461.1% in the 1st quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock worth $37,849,000 after buying an additional 234,446 shares during the last quarter. Bessemer Group Inc. lifted its position in Ascendis Pharma A/S by 61.0% in the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after buying an additional 332 shares during the last quarter. Finally, Nan Fung Group Holdings Ltd bought a new stake in Ascendis Pharma A/S in the 1st quarter worth approximately $2,056,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.